StemCell Therapy

GA is a progressive, irreversible retinal disease that could lead to blindness. Credit: Kamil Saitov.

Boehringer Ingelheim has signed a collaboration and licensing agreement with CDR-Life for the research and development of antibody fragment-based therapeutics to treat geographic atrophy (GA).

GA is a progressive, irreversible retinal disease that develops in patients with age-related macular degeneration (AMD) that could lead to blindness and lacks approved treatments.

The partnership will combine Boehringers therapeutic biologics development expertise with CDR-Lifes antibody engineering expertise. The companies intend to advance CDR-Lifes preclinical candidate for potentially preserving sight in GA patients.

Boehringer Ingelheim discovery research corporate senior vice-president and global head Clive Wood said: Partnering with CDR-Life provides Boehringer Ingelheim with the opportunity to collaborate with a team that has a proven track record developing antibody fragment-based therapeutics for retinal diseases.

The prospect of losing ones sight is frightening. We are committed to transformational therapies that have the potential to succeed in preserving the health and vision of patients with retinal diseases, such as geographic atrophy.

Antibody fragment-based technology helps to retain the specificity of an antibody and also significantly cuts the molecules size, noted Boehringer. This technology could have a significant benefit over standard large molecule approaches for retinal diseases treatment.

The company added that intravitreal injection to the eye may enable high-affinity antibody fragment therapies to reach the retinal pigment epithelial cells, where degeneration occurs.

This precise delivery of medication is expected to mitigate the cellular stresses associated with AMD and prevent further loss of sight.

CDR-Life CEO Christian Leisner said: This is an exciting partnership that brings together Boehringer Ingelheims development expertise and CDR-Lifes innovative antibody fragments to provide hope for people living with a blinding retinal disease.

We look forward to advancing this project towards the clinic together with the Boehringer Ingelheim team.

As part of the deal, Boehringer will get an exclusive, worldwide licence to develop compounds based on CDR-Lifes technology against a specific target. The company will carry out development and commercialisation globally.

CDR-Life will be eligible for up to CHF474.5m ($488.9m) in upfront and milestone payments, along with research funding and sales royalties.

Read the original here:
CDR-Life and Boehringer partner to develop geographic atrophy therapies - Pharmaceutical Technology

This entry was posted on May 14, 2020 at 8:43 am and is filed under Eye Sight & Vision. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |